Targeting O-GlcNAcylated METTL3 impedes MDS/AML progression via diminishing SRSF1 m<sup>6</sup>A modification.

It showed an increasing trend with the progression of myeloma and correlated with worse clinical features and poorer outcomes. 31 , 32 Moreover, SRSF1 levels were maintained in CD34 + chronic myeloid leukemia progenitors by cytokines despite effective BCR-ABL1 inhibition, and increased levels of SRSF1 promote impaired imatinib

also in 63,971 other papers